Major CVS shareholder plans activist push, meet with execs: sources

Major CVS shareholder plans activist push, meet with execs: sources

CVS Pharmacy logo is seen at store in Florida Keys, United States on May 7, 2024.  Jakub Porzycki | Nurphoto | Getty Images Glenview Capital, a major CVS Health shareholder, is expected to meet with company leadership on Monday to lay out proposed fixes for the struggling business, according to people familiar with the matter, … Read more

Humira sales are falling, but AbbVie has successors

Humira sales are falling, but AbbVie has successors

Humira, the injectable rheumatoid arthritis treatment is pictured in a pharmacy in Cambridge, Massachusetts. JB Reed | Bloomberg | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Sales of AbbVie‘s Humira are plummeting as the once-top-selling drug fights competition from cheaper … Read more

FTC challenges patents held by drugmakers, including for Ozempic

FTC challenges patents held by drugmakers, including for Ozempic

A box of Ozempic and contents sit on a table in Dudley, North Tyneside, Britain, October 31, 2023.  Lee Smith | Reuters The Federal Trade Commission on Tuesday said it is challenging hundreds of alleged “junk” patents held by pharmaceutical companies for 20 brand-name drugs, including Novo Nordisk’s blockbuster diabetes drugs Ozempic, Saxenda and Victoza. … Read more

Big pharma Merck, Bristol Myers, J&J prepare to lose revenue

Big pharma Merck, Bristol Myers, J&J prepare to lose revenue

The New York Stock Exchange welcomes Johnson & Johnson (NYSE: JNJ) to the podium.  NYSE Big pharmaceutical companies such as Bristol Myers Squibb, Merck and Johnson & Johnson face a looming threat that will put tens of billions of dollars in sales at risk between now and 2030, as blockbuster drugs will tumble off a … Read more

Fed-induced rally is unsustainable, especially for 5 sectors

Fed-induced rally is unsustainable, especially for 5 sectors

It’s not being talked about enough. This market move off the November lows and the Fed pivot — signaling an end to the central bank’s rate-hiking cycle — is one of the most astonishing and satisfying I have seen in 43 years of investing. In nine weeks, we blew through price targets on so many … Read more